Travere Therapeutics Inc Aktie News

SAN DIEGO, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Travere Therapeutics, Inc. (NASDAQ: TVTX). If you have information that could assist in the Travere investigation or if you are a Travere investor who suffered a loss and would like to learn more, you can provide your information here: htt...

Travere Therapeutics (TVTX) is focused on rare kidney diseases, with FILSPARI driving significant revenue growth in IgA Nephropathy (IgAN). Competition in IgAN from larger players like Novartis and Vertex is intensifying, making FILSPARI's FSGS approval pivotal for the company's future growth. FILSPARI's FSGS indication represents a $2 billion U.S. peak sales opportunity, with no current FDA-ap...

SAN DIEGO, Jan. 28, 2026 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Travere Therapeutics, Inc. (NASDAQ: TVTX). If you have information that could assist in the Travere investigation or if you are a Travere investor who suffered a loss and would like to learn more, you can provide your informati...

BOSTON, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Travere Therapeutics, Inc. (Nasdaq: TVTX) for potential securities law violations. Investors who have lost money in their Travere Therapeutics, Inc. investment should contact the firm to learn more about how they might recover those losses.

Palisades added 137,768 shares of Travere Therapeutics; estimated trade size $5.26 million based on quarterly average price. The position represents 1.99% of 13F assets under management (AUM).

Palisades added 137,768 shares of Travere Therapeutics; estimated trade size $5.26 million based on quarterly average price. The position represents 1.99% of 13F assets under management (AUM).

SAN DIEGO--(BUSINESS WIRE)---- $TVTX #TVTX--Robbins Geller is investigating whether Travere and certain of its top executives made materially false and/or misleading statements to investors.

ATLANTA, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Travere Therapeutics, Inc. (“Travere” or the “Company”) (NASDAQ: TVTX) complied with federal securities laws. On January 13, 2026, Travere disclosed that the U.S. Food and Drug Administration has extended the review timeline of its supplemental New Drug Application for FILSPARI® (sparsentan) in focal segmen...